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ing author. Tel.: +353 1
ess: stephen.lane@amnSummary Asthma is a common chronic condition that places substantial burden on
patients and healthcare services. Despite the standards of asthma control that
international guidelines recommend should be achieved, many patients continue to
suffer sub-optimal control of symptoms and experience exacerbations (acute asthma
attacks). In addition to being associated with reduced quality of life, asthma
exacerbations are a key cost driver in asthma management.
Routine clinical practice for the management of asthma exacerbations varies in
different healthcare systems, so healthcare providers require local costs to be able
to assess the value of therapies that reduce the frequency and severity of
exacerbations. This prospective study, conducted in a total of 15 countries, assessed
the local cost of asthma exacerbations managed in either primary or secondary care.
Healthcare resources used were costed using actual values appropriate to each
country in local currency and in Euros.
Results are presented for exacerbations managed in primary care in Brazil,
Bulgaria, Croatia, Czech Republic, Hungary, Poland, Russia, Slovakia, Slovenia, Spain
and Ukraine, and in secondary care in Croatia, Denmark, Ireland, Latvia, Norway,
Poland, Russia, Slovakia, Slovenia and Spain.
Multiple regression analysis of the 2052 exacerbations included in the economic
analysis showed that the cost of exacerbations was significantly affected by country
(Po0:0001). Mean costs were significantly higher in secondary care (h1349) than
primary care (h445, P ¼ 0:0003). Age was a significant variable (P ¼ 0:0002), though
the effect showed an interaction with care type (Po0:0001). As severity of
exacerbation increased, so did secondary care costs, though primary care costs
remained essentially constant.Elsevier Ltd. All rights reserved.
4144031; fax: +353 1 4142989.
ch.ie (S. Lane).
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Cost of asthma exacerbations 435In conclusion, the study showed that asthma exacerbations are costly to manage,
suggesting that therapies able to increase asthma control and reduce the frequency
or severity of exacerbations may bring economic benefits, as well as improved
quality of life.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Asthma is a common chronic condition, charac-
terised by inflammation of the airways and con-
sequent airflow limitation.1 Despite the standards
of asthma control that national and international
guidelines recommend should be achieved,1–3 many
patients continue to suffer sub-optimal control of
symptoms, exacerbations and impairment in qual-
ity of life.4–6
In addition to the burden on the patient, asthma
places considerable demands on the healthcare
services in developed countries, comparable to the
burden of diabetes and hypertension.7–11 The total
annual cost of asthma is estimated at $US 400
million in Australia and $US 621 billion in the USA.10
Such information is not currently available for many
other countries. Asthma exacerbations (acute asth-
ma attacks) are a key cost driver in asthma
management.7,8,12 Retrospective analysis of a large
data set, covering the routine management of more
than 12,000 asthmatic patients in general practice
in the UK, showed that the average cost of
managing a patient who had suffered an asthma
exacerbation was £381 per annum, more than three
times greater than the cost for a patient who did not
experience an exacerbation (£108).7 The higher cost
per patient among those experiencing exacerba-
tions was maintained across the range of asthma
severity (defined according to previous maintenance
treatment) from mild to severe. Exacerbations
requiring hospitalisation are particularly costly.13
Routine clinical practice for the management of
asthma exacerbations varies in different healthcare
systems. For example, hospital admission rates for
asthma in children aged 5–9 years has declined in
the Netherlands in recent years to 4–5 admissions/
10,000 population, compared with the rising
admission rate for children of the same age in the
UK, amounting to 20–30 admissions/10,000 popula-
tion.14 Extrapolation of costs from a system where
the majority of exacerbations are managed in the
community may underestimate the cost for a
healthcare system where hospitalisation is the
normal approach, while the converse also applies.
This prospective study, conducted in a total of 15
countries, aimed to describe the local Cost Of
Asthma eXacerbations (COAX) managed in eitherprimary or secondary care, to provide country-
specific data. With the collection of a considerable
database on exacerbations, there was also the
opportunity to examine determinants of costs,
using multivariate analysis.Methods
Study design
This survey of the COAX was designed as an
international observational study, with data from
each country collected and analysed separately.
Investigators used international guidelines to de-
fine asthma, exacerbations and resolution.1 The
management of exacerbations followed the usual
clinical practice for each country. Participating
countries started and ended recruitment to the
study independently, and included as many or as
few centres as they considered appropriate.
Two studies were run in parallel–one in primary
care and the other in secondary care–to address the
differing ways that asthma exacerbations are
managed. Participating countries could collect data
on either or both sites of healthcare delivery.
Information on utilisation of healthcare services
(e.g. primary care contacts, hospital contacts,
emergency room visits) and asthma medication
was recorded prospectively.
Data collection
To achieve economies of scale and facilitate
subsequent analysis, all participating countries
used a common case report form to collect data,
with two versions developed to capture the
differences in treatment practice in the primary
and secondary care settings. As the studies in each
country were independent of each other, the time
frame for recruitment and data collection varied.
Patients
Patients recruited into the study were aged 18 years
or more, with a confirmed diagnosis of asthma (of
any severity), presenting with an exacerbation of
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S. Lane et al.436asthma on a non-routine visit to either a primary
care or secondary care site (as appropriate for the
study). Individual countries were permitted to
introduce country-specific amendments to the inclu-
sion criteria to satisfy local regulatory requirements.
The only exclusion criteria were current involvement
of the patient in any other clinical trial for asthma,
or previous inclusion in the exacerbation study. Each
participating country aimed to recruit approximately
100 patients.Description of local COAX
Analysis for each participating country was con-
ducted centrally, on a per country basis, from the
perspective of the healthcare system. The health-
care resources used (consultations, hospitalisa-
tions, medication, devices prescribed, tests
undertaken, etc.) were costed for each patient
using actual values appropriate to each country in
local currency (e.g. local drug tariff, local in-
patient costs) and, to facilitate subsequent analy-
sis, in Euros. In order to take into account the
varying doses of medication and duration of
treatment, the smallest dose of the drug available
in each country was used as the unit of delivery.
The total number of these units for each drug used
during an exacerbation was determined for each
patient, and multiplied by the local unit cost to
obtain the total drug cost of the exacerbation for
the patient. The mean cost of each medication was
then calculated. Statistical analysis of costs (95%
confidence intervals) was based on bootstrapping.15Multiple regression analysis
A multiple regression model was used to analyse
the determinants of costs. The model included as
variables the country, age of patient, gender,
asthma severity and exacerbation severity. As the
number of subjects in the most severe category for
exacerbation severity (respiratory arrest imminent)
was low (n ¼ 17), this group were combined with
those in the severe exacerbation category. The
order of the inclusion of these terms into the model
was decided by which variables explained the most
variation in the model. In addition, other variables
considered for inclusion in the model were care
type (primary or secondary) and years since
diagnosis. Potential interactions considered were
asthma severity/age, care type/age, care type/
asthma severity, care type/exacerbation severity
and care type/asthma severity/age.
For the main effect terms, an F-test was used to
determine whether the individual terms weresignificant at the 5% level. Significant terms
were included in the model. The interaction terms
were included if significant at the 10% level. If an
interaction term was included, then the individual
terms that contributed to the interaction were
included, regardless of significance.Results
Demographics and baseline characteristics
A total of 1201 patients were recruited into the
primary care study from 11 countries (Brazil,
Bulgaria, Croatia, Czech Republic, Hungary, Poland,
Russia, Slovakia, Slovenia, Spain, Ukraine). The
secondary care study involved 1124 patients from
10 countries (Croatia, Denmark, Ireland, Latvia,
Norway, Poland, Russia, Slovakia, Slovenia and
Spain). Tables 1 and 2 summarise the demographic
and baseline characteristics of the patients in-
cluded in the analysis. A total of 2052 patients were
included in the efficacy evaluable per protocol
population used for the economic analyses, which
excluded those inappropriately recruited to the
intent to treat population and those for whom full
economic data was not available.
Description of local COAX
The COAX reflects both the local unit prices for
medications, consultations and tests (influenced by
economic factors within each country), and the
amount of healthcare resources used (influenced by
management practices within each country). Con-
sequently, the results of the analyses are presented
separately for each country. Primary care and
secondary care data for two illustrative countries
(Poland and Spain) are presented in Tables 3 and 4.
In the Appendix, the costs of asthma exacerbations
in other countries are summarised for primary care
management in Tables 7–15 and for secondary care
management in Tables 16–23.
Determinants of costs
A total of 2052 exacerbations of asthma were
included in the multiple regression analysis to
assess factors influencing costs. As expected, costs
between countries differed significantly, so the
stratifying term, country, was highly significant
(Po0:0001). There was no significant difference in
costs between male and female patients (P ¼
0:0649). There was a significant association with
the care type (P ¼ 0:0003), with the cost of an
ARTICLE IN PRESS
Table 2 Demographics and baseline characteristics of patients included in the secondary care study.
Country Number Mean age
(years) SD
% male Severity of asthma Severity of current
exacerbation
% mild % moderate/
severe
%
mild
%
moderate
% severe/
RAI
Croatia 110 47.4 (16.1) 32 42 58 5 43 53
Denmark 101 37.2 (14.6) 26 50 50 18 45 36
Ireland 105 37.3 (15.6) 32 49 51 19 36 45
Latvia 99 51.7 (16.7) 29 19 81 8 77 15
Norway 100 41.6 (14.0) 37 35 65 5 59 36
Poland 123 44.4 (17.2) 33 34 66 20 42 37
Russia 149 51.0 (16.7) 46 31 69 11 52 38
Slovakia 101 51.7 (16.1) 40 40 60 17 63 20
Slovenia 110 40.8 (9.9) 45 43 57 25 43 32
Spain 126 50.2 (20.7) 27 58 42 33 39 28
RAI, respiratory arrest imminent.
Table 1 Demographic and baseline characteristics of patients included in the primary care study.
Country Number Mean age
(years) SD
% male Severity of asthma Severity of current
exacerbation
% mild % moderate/
severe
%
mild
%
moderate
% severe/
RAI
Brazil 145 39.8 (15.4) 43 71 29 55 33 12
Bulgaria 71 43.7 (15.6) 42 39 61 17 62 21
Croatia 121 51.8 (18.8) 40 52 48 22 55 22
Czech Republic 93 44.5 (15.3) 29 34 66 38 56 6
Hungary 120 45.5 (14.7) 34 50 50 16 64 20
Poland 116 44.3 (15.8) 41 46 54 28 64 9
Russia 100 51.1 (14.1) 34 24 76 57 40 3
Slovakia 102 47.0 (14.2) 30 34 66 15 66 20
Slovenia 100 53.3 (17.0) 43 72 28 22 49 29
Spain 133 47.8 (19.6) 26 54 46 44 44 13
Ukraine 100 42.5 (10.5) 40 27 73 0 65 35
RAI, respiratory arrest imminent.
Cost of asthma exacerbations 437exacerbation managed in secondary care estimated
at h1349 (95% CI: 1271, 1427), compared with the
cost of primary care management of h445 (95% CI:
376, 515).
Age was a significant variable (P ¼ 0:0002),
though the effect showed an interaction with care
type (Po0:0001). The cost of secondary care
showed an increase with increasing age of patient,
though the cost of primary care remained stable,
regardless of age (Table 5). Costs associated with
asthma severity were broadly similar for intermit-
tent (h829), mild persistent (h807) and moderate
persistent (h880), though the cost increased sig-
nificantly for severe persistent asthma (h1073,
P ¼ 0:0004).As severity of exacerbation increased, so did
costs (Po0:0001) (Table 6). There was evidence of
an interaction between exacerbation severity and
care type (Po0:0001). Although for patients man-
aged in primary care, costs were similar regardless
of severity, for those managed in secondary care,
costs increased as exacerbation severity increased.Discussion
Increasingly, national prescribing authorities re-
quire health economic data to assist with decisions
on priorities and budgets for healthcare. Such data
is most meaningful if collected in the country
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Table 5 Estimated costs associated with care type predicted at different ages.
Age Estimated cost of primary
care management
(h, 95% CI)
Estimated cost of
secondary care
management (h, 95% CI)
35 years (approximate age of lower quartile) 448 (368, 528) 1239 (1154, 1325)
50 years (approximate median age) 445 (375, 515) 1377 (1298, 1456)
65 years (approximate age of upper quartile) 441 (351, 531) 1515 (1413, 1617)
Table 6 Estimated costs associated with care type according to exacerbation severity.
Exacerbation severity Estimated cost of
exacerbation (h, 95% CI)
Estimated cost of primary
care management
(h, 95% CI)
Estimated cost of
secondary care
management (h, 95% CI)
Mild 737 (638, 836) n ¼ 428 450 (344, 555) n ¼ 311 1024 (861, 1187) n ¼ 117
Moderate 881 (820, 941) n ¼ 1091 456 (375, 538) n ¼ 609 1305 (1215, 1396) n ¼ 482
Severe/RAI 1074 (989, 1159) n ¼ 533 430 (294, 566) n ¼ 180 1718 (1616, 1821) n ¼ 353
RAI, respiratory arrest imminent
S. Lane et al.440concerned, following patterns of treatment in
common use in that country. The COAX study was
designed to give a baseline assessment of the cost
of managing asthma exacerbations, using country-
specific management practices and local costs. The
data presented here should be of value to local
healthcare managers and others, when assessing
the benefits of treatments that reduce the fre-
quency and/or severity of exacerbations.
In addition to determining the real life cost of an
asthma exacerbation, the study revealed the varied
approaches to management in the participating
countries. International guidelines recommend ap-
propriate assessments and treatments for the man-
agement of exacerbations,1 and these are broadly
supported by national guidelines (see for e.g. Refs.
2,3) though it is possible that variation in case load
underlies the differences in treatments given, it is
more likely that recommendations are not being
implemented. The reasons may vary in different
countries, but could include lack of awareness of
guidelines, lack of availability of appropriate tests
and/or medications and lack of resources to fund
appropriate tests and/or management. Further work
within each country would be required to examine
these issues. The findings reported here provide
baseline assessments for future national studies to
compare treatment approaches and subsequent
costs arising from exacerbations.
The aim of the study was to collect ‘real life’
data and assess routine clinical practice, so inclu-
sion criteria were kept to a minimum. Conse-
quently, there is at least a theoretical possibility of
selection bias in the patients recruited to the study.
Nevertheless, in such a descriptive study, anyselection bias does not invalidate the findings.
Participating clinicians were responsible for asses-
sing the severity of asthma, severity of exacerba-
tion and duration of exacerbation, based on
international guidelines.1 It is possible that the
interpretation of asthma severity, and exacerbation
severity/duration varied in different sites, particu-
larly if these guidelines have little influence on
routine practice. Another potential criticism of the
methodological approach is the use of the smallest
dose of medication to cost the treatment. Patients
were expected to receive a range of different doses
of a medication, for different duration. By adopting
the smallest possible dose as the unit of counting,
the total number of units could be assessed, taking
into account both the magnitude of the dose
prescribed and the duration of treatment. The
disadvantage of the approach is that the lowest
dose of a medication may be priced proportionately
higher than a higher dose, thereby artificially
inflating the cost of the treatment. Consequently,
the contribution of medication costs may be some-
what lower than estimated here.
Although common data collection forms and
analysis were used in this study, this was to address
practical issues and does not imply that it was
designed as a comparative study. However, with a
large database of exacerbations it was possible to
use multivariate analysis to assess cost drivers. As
expected, the cost of an exacerbation was shown to
be highly dependent on the country where it
occurs, presumably as a consequence of cost
structures, absolute cost levels and management
approaches. The results also confirmed previous
studies showing the higher cost of exacerbations
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previous studies, the cost also tended to increase
with severity of the exacerbation,16–18 though the
present analysis showed that this applied only to
exacerbations managed in secondary care. Exacer-
bations in older patients were more costly to
manage than in younger patients, possibly because
of an increased need for secondary care manage-
ment. Interestingly, severity of the underlying
asthma showed little influence on the cost of
exacerbation management, presumably because
patients with uncontrolled asthma of all severities
may experience exacerbations. This finding appears
to confirm a recent report that patients classified as
having mild asthma experienced almost as many
severe exacerbations as those classified with mod-
erate or severe disease.19 Furthermore, the finding
provides additional support to the view that severity
is not a useful method of classifying asthma, with
asthma control being a more relevant concept.19
The study showed the high cost of managing each
exacerbation, particularly those managed in sec-
ondary care settings. Therapies associated with a
reduction in frequency and/or severity of exacer-Table 7 Cost of an exacerbation managed in primary ca
Unit cost, national cu
Main medications Mean per person
Anticholinergics —
Antibiotics —
Inhaled steroids 0.4 (0.3)
LABA —
Oral steroids 16.3 (10.3)
SABA 0.2 (0.1)
Theophyllines 1.0 (0.7)
Main tests Per test
PEF 2 (1.26)
Spirometry 48 (30.33)
Main contacts Per contact
Nurse 14 (8.53)
Doctory 39/18 (24.64/11.37)
Mean cost of medications and devices
95% CI, national currency (h)
Mean cost of tests, contacts
95% CI, national currency (h)
Mean total direct cost
95% CI, national currency (h)
Ninety-three patients included in economic analysis, mean durati
successfully in primary care.
For exacerbation, most commonly Berotec (used by 55% of p
patients, mean use 448 units).
yInitial/follow-up.bations may bring economic benefits, as well as
reducing patient suffering. There are some indica-
tions from retrospective analysis of prescribing
patterns that the use of inhaled corticosteroids
may reduce the likelihood of hospitalisation for
asthma exacerbations, and accident and emergency
visits,20,21 while the use of both inhaled corticos-
teroid and long-acting inhaled bronchodilators may
also have beneficial effects on exacerbation rates,
in comparison to either treatment alone.22,23 In
clinical trials, treatments such as the combination
of inhaled corticosteroid, fluticasone propionate,
and long-acting b2-agonist, salmeterol, have been
shown to reduce the number of moderate and/or
severe exacerbations, compared with other thera-
pies, in patients with asthma previously sympto-
matic on inhaled corticosteroids alone, contributing
to lower overall management costs.24
A clear aim of international management guide-
lines is to use medication to achieve control
of asthma, as evidenced by minimal daytime
and nighttime symptoms, minimal impact on
daily functioning and no exacerbations.1 Patients
recruited to this study were experiencing anre in Brazil.
rrency (h) % patients using resource
31
—
2
—
26
59
28
0
o1
22
98
103.1 (65.2)
69.2, 161 (43.7, 101.7)
57.8 (36.5)
51.1, 65.6 (32.3, 41.4)
160.9 (101.7)
126.7, 220.6 (80.0, 139.4)
on of exacerbation 4.0 days (SD 5.0), 60% of patients managed
atients, mean use 7 units) and aminofilina (used by 28% of
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Table 8 Cost of an exacerbation managed in primary care in Bulgaria.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics Not collected 0
Antibiotics 47.0 (24.2) 46
Inhaled steroids 17.7 (9.1) 90
LABA 23.2 (11.9) 16
Oral steroids 2.0 (1.1) 43
SABA 6.1 (3.1) 25
Theophyllines 1.1 (0.6) 7
Main tests Per test
PEF 2.0 (1.03) 65
Spirometry 17.0 (8.75) 100
Main contacts Per contact
Nurse 3.0 (1.54) 81
Doctory 9.0/5.0 (4.63/2.57) 100
Mean cost of medications and devices 66.7 (34.3)
95% CI, national currency (h) 48.8, 86.7 (25.1, 44.6)
Mean cost of tests, contacts 89.8 (46.2)
95% CI, national currency (h) 83.3, 96.5 (42.9, 49.6)
Mean total direct cost 156.4 (80.5)
95% CI, national currency (h) 134.9, 181.2 (69.4, 93.2)
Sixty-eight patients included in economic analysis, mean duration of exacerbation 12.6 days (SD 6.2), 97% of patients managed
successfully in primary care.
For exacerbation, most commonly Becloforte (used by 56% of patients, mean use 7520 units), prednisolone (used by 35% of
patients, mean use 343 units) and Ventolin (used by 22% of patients, mean use 1213 units).
yInitial/follow-up.
Table 9 Cost of an exacerbation managed in primary care in Croatia.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics 11.5 (1.6) 4
Antibiotics 112.5 (15.3) 42
Inhaled steroids 33.5 (4.5) 55
LABA 71.6 (9.7) 25
Oral steroids 31.2 (4.2) 25
SABA 9.2 (1.3) 68
Theophyllines 10.3 (1.4) 29
Main tests Per test
PEF 25.94 (3.52) 45
Spirometry 57.01 (7.74) 45
Main contacts Per contact
Nurse 13.29 (1.80) 43
Doctory 52.73/25.31 (7.16/3.44) 95
Mean cost of medications and devices 284.4 (38.6)
95% CI, national currency (h) 227.5, 352.0 (30.9, 47.8)
Mean cost of tests, contacts 228.7 (31.1)
95% CI, national currency (h) 199.1, 266.4 (27.0, 36.2)
Mean total direct cost 513.1 (69.7)
95% CI, national currency (h) 443.6, 593.1 (60.2, 80.5)
One hundred and twenty patients included in economic analysis, mean duration of exacerbation 14.9 days (SD 14.0), 98% of
patients managed successfully in primary care.
For exacerbation, most commonly Ventolin (used by 68% of patients, mean use 5379 units), Becotide (used by 26% of
patients, mean use 2745 units), Serevent (used by 25% of patients, mean use 574 units) and Aminophyllin (used by 20% of
patients, mean use 832 units).
yInitial/follow-up.
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Table 10 Cost of an exacerbation managed in primary care in Czech Republic.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics 84.9 (2.4) 10
Antibiotics 397.3 (11.4) 24
Inhaled steroids 219.0 (6.3) 48
LABA 309.0 (8.9) 20
Oral steroids 91.0 (2.6) 49
SABA 35.5 (1.0) 36
Theophyllines 60.4 (1.7) 22
Main tests Per test
PEF 108 (3.11) 36
Spirometry 540 (15.55) 94
Main contacts Per contact
Nurse 196.0 (5.64) 3
Doctory 170/85 (4.89/2.45) 72
Mean cost of medications and devices 510.6 (14.7)
95% CI, national currency (h) 362.5, 684.1 (10.4, 19.7)
Mean cost of tests, contacts 915.0 (26.3)
95% CI, national currency (h) 822.1, 1006.3 (23.7, 29.0)
Mean total direct cost 1425.6 (41.0)
95% CI, national currency (h) 1224.3, 1638.9 (35.2, 47.2)
Eighty-seven patients included in economic analysis, mean duration of exacerbation 12.5 days (SD 7.4), 66% of patients managed
successfully in primary care.
For exacerbation, most commonly Prednison (used by 38% of patients, mean use 119 units) and Pulmicort (used by 17% of
patients, mean use 11,760 units).
yInitial/follow-up
Table 11 Cost of an exacerbation managed in primary care in Hungary.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics 116.3 (0.4) 5
Antibiotics 882.2 (3.4) 11
Inhaled steroids 144.6 (0.6) 54
LABA 238.1 (0.9) 23
Oral steroids 85.7 (0.3) 40
SABA 81.9 (0.3) 33
Theophyllines 75.9 (0.3) 36
Main tests Per test
PEF 250 (0.95) 38
Spirometry 250 (0.95) 97
Main contacts Per contact
Nurse 200 (0.76) 76
Doctory 500/400 (1.91/1.53) 100
Mean cost of medications and devices 645.9 (2.5)
95% CI, national currency (h) 434.6, 876.0 (1.7, 3.3)
Mean cost of tests, contacts 3175.1 (12.1)
95% CI, national currency (h) 2916.5, 3467.7 (11.1, 13.2)
Mean total direct cost 3821.0 (14.6)
95% CI, national currency (h) 3441.9, 4225.2 (13.1, 16.1)
One hundred and twelve patients included in economic analysis, mean duration of exacerbation 12.8 days (SD 16.2), 96% of
patients managed successfully in primary care.
For exacerbation, most commonly Pulmicort (used by 35% of patients, mean use 5482 units), Flixotide (used by 20% of
patients, mean use 2693 units) and Serevent (used by 20% of patients, mean use 830 units);
yInitial/follow-up.
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Table 12 Cost of an exacerbation managed in primary care in Russia.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics 148.2 (6.3) 1
Antibiotics 26.4 (1.1) 1
Inhaled steroids 4145.5 (176.6) 85
LABA 318.4 (13.6) 14
Oral steroids 316.4 (13.5) 12
SABA 406.4 (17.3) 64
Theophyllines 13.7 (0.6) 62
Main tests Per test
PEF 12 (0.51) 68
Spirometry 32 (1.37) 99
Main contacts Per contact
Nurse 6 (0.25) 13
Doctory 17/13 (0.73, 0.56) 94
Mean cost of medications and devices 5001.8 (213.0)
95% CI, national currency (h) 956.5, 15019.3 (40.7, 639.7)
Mean cost of tests, contacts 137.0 (5.8)
95% CI, national currency (h) 123.9, 151.5 (5.3, 6.5)
Mean total direct cost 5138.8 (218.9)
95% CI, national currency (h) 1084.5, 15150.1 (46.2, 645.2)
Ninety-nine patients included in economic analysis, mean duration of exacerbation 15.9 days (SD 5.3), 99% of patients managed
successfully in primary care.
For exacerbation, most commonly Theopec (used by 57% of patients, mean use 2188 units), Ventolin (used by 54% of
patients, mean use 5183 units) and Flixotide (used by 42% of patients, mean use 11,065 units).
yInitial/follow-up.
Table 13 Cost of an exacerbation managed in primary care in Slovakia.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics 67.4 (1.5) 17
Antibiotics 678.7 (15.6) 24
Inhaled steroids 527.2 (12.1) 72
LABA 398.3 (9.1) 22
Oral steroids 510.8 (11.7) 58
SABA 4185.7 (96.1) 45
Theophyllines 82.9 (1.9) 22
Main tests Per test
PEF 118 (2.71) 44
Spirometry 505 (11.60) 77
Main contacts Per contact
Nurse 13 (0.30) 2
Doctory 26 (0.59) 94
Mean cost of medications and devices 3382.1 (77.7)
95% CI, national currency (h) 1278.6, 6200.4 (29.4, 142.4)
Mean cost of tests, contacts 1193.6 (27.4)
95% CI, national currency (h) 955.6, 1478.4 (21.9, 33.9)
Mean total direct cost 4575.7 (105.1)
95% CI, national currency (h) 2451.8, 7399.6 (56.3, 169.9)
One hundred and two patients included in economic analysis, mean duration of exacerbation 18.7 days (SD 12.8), 86% of patients
managed successfully in primary care
For exacerbation, most commonly Prednison (used by 34% of patients, mean use 96 units), Flixotide (33% of patients, mean
use 8949 units), Serevent (21% of patients, mean use 1612 units).
yInitial/follow-up.
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Table 14 Cost of an exacerbation managed in primary care in Slovenia.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics — —
Antibiotics 3828.1 (18.6) 36
Inhaled steroids 2136.3 (10.4) 55
LABA 1818.9 (8.9) 15
Oral steroids 1806.9 (8.8) 44
SABA 519.8 (2.5) 68
Theophyllines 176.5 (0.9) 27
Main tests Per test
PEF N/C 53
Spirometry 2550 (12.42) 28
Main contacts Per contact
Nurse — —
Doctory 1218/778 (5.93/3.79) 100
Mean cost of medications and devices 11304.6 (55.0)
95% CI, national currency (h) 8431.0, 14150.1 (41.0, 68.9)
Mean cost of tests, contacts 6213.3 (30.3)
95% CI, national currency (h) 5120.7, 7048.5 (24.9, 36.3)
Mean total direct cost 17517.9 (85.3)
95% CI, national currency (h) 14054.4, 20747.5 (68.4, 101.0)
Ninety-one patients included in economic analysis, mean duration of exacerbation 15.1 days (SD 8.0), 93% of patients managed
successfully in primary care
For exacerbation, most commonly Berodual (used by 38% of patients, mean use 3881 units). Flixotide (used by 36% of
patients, mean use 16,424 units) and Ventolin (used by 35% of patients, mean use 8192 units).
yInitial/follow-up
Table 15 Cost of an exacerbation managed in primary care in Ukraine.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics — —
Antibiotics 170.7 (37.2) 9
Inhaled steroids 41.6 (9.1) 76
LABA 50.0 (10.9) 35
Oral steroids 32.3 (7.0) 40
SABA 0.6 (0.1) 68
Theophyllines 2.1 (0.5) 19
Main tests Per test
PEF 2.04 (0.45) 79
Spirometry 12.90 (2.81) 93
Main contacts Per contact
Nurse 0.98 (0.21) 79
Doctory 2.90/2.00 (0.63/0.44) 100
Mean cost of medications and devices 180.9 (39.5)
95% CI, national currency (h) 153.5, 210.1 (33.5, 45.8)
Mean cost of tests, contacts 80.8 (17.6)
95% CI, national currency (h) 73.8, 88.1 (16.1, 19.2)
Mean total direct cost 261.8 (57.1)
95% CI, national currency (h) 232.7, 293.1 (50.8, 63.9)
Eighty patients included in economic analysis, mean duration of exacerbation 11.7 days (SD 5.8), 95% of patients managed
successfully in primary care
For exacerbation, most commonly Ventolin (used by 44% of patients, mean use 889 units), Serevent (used by 35% of patients,
mean use 591 units) and Flixotide (used by 34% of patients, mean use 4690 units).
yInitial/follow-up.
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Table 16 Cost of an exacerbation managed in secondary care in Croatia.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics 862.6 (117.1) 2
Antibiotics 129.8 (17.6) 38
Inhaled steroids 50.8 (6.9) 43
LABA 67.3 (9.1) 23
Oral steroids 80.2 (10.9) 84
SABA 1341.9 (182.2) 51
Theophyllines 32.2 (4.4) 92
Hospital time Per day (Mean length of stay)
Emergency room 527.25 (71.59) 43 (3.0 h)
Respiratory ward 130.13 (17.67) 100 (9.2 days)
Intensive care unit 1666.39 (10.58) 15 (59.1 h)
Other direct costs Per test
PEF 25.94 (3.52) 56
Spirometry 57.01 (7.74) 100
Outpatient visit 77.89 (10.58) 93
Mean cost of medications and devices 1888.2 (256.4)
95% CI, national currency (h) 1083.9, 3176.5 (147.2, 431.3)
Mean cost hospital time 1893.8 (257.1)
95% CI, national currency (h) 1497.6, 2376.6 (203.4, 322.7)
Other direct costs 534.8 (72.6)
95% CI, national currency (h) 464.9, 609.7 (63.1, 82.8)
Mean total direct cost 4316.7 (586.2)
95% CI, national currency (h) 3301.9, 5867.1 (448.4, 796.7)
Eighty-seven people included in economic analysis, mean duration of exacerbation 14.7 days (SD 10.2).
For exacerbation, most commonly Solu-medrol (used by 49% of patients, mean use 442 units), Ventolin (used by 49% of
patients, mean use 8788 units) and Aminophylline (used by 46% of patients, mean use 3900 units)
Table 17 Cost of an exacerbation managed in secondary care in Denmark.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics 36.0 (4.8) 21
Antibiotics 210.1 (28.2) 13
Inhaled steroids 67.8 (9.1) 36
LABA 89.3 (12.0) 23
Oral steroids 101.3 (13.6) 66
SABA 107.3 (14.4) 72
Theophyllines 904.1 (121.4) 2
Hospital time Per day (Mean length of stay)
Emergency room 16714.00 (2244.98) 77 (10.7 h)
Respiratory ward 3831.11 (514.58) 62 (3.6 days)
Intensive care unit 16714.00 (2244.98) 2 (48 h)
Other direct costs Per test
PEF 31.34 (4.21) 80
Spirometry 210.41 (28.26) 53
Outpatient visit 1339.00 (179.85) 80
Mean cost of medications and devices 912.2 (122.5)
95% CI, national currency (h) 668.9, 1214.8 (89.8, 163.2)
Mean cost hospital time 17815.1 (2392.9)
95% CI, national currency (h) 14949.8, 21103.2 (2008.0, 2834.5)
Other direct costs 1019.3 (136.9)
95% CI, national currency (h) 930.3, 1114.0 (125.0, 149.6)
Mean total direct cost 19746.6 (2652.3)
95% CI, national currency (h) 16770.6, 23356.5 (2252.6, 3137.2)
Ninety-two people included in economic analysis, mean duration of exacerbation 6.3 days (SD 6.5).
For exacerbation, most commonly Prednisolone (used by 52% of patients, mean use 222 units) and Bricanyl (used by 51% of
patients, mean use 4350 units).
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Table 18 Cost of an exacerbation managed in secondary care in Ireland.
Unit cost, h % patients using resource
Main medications Mean per person
Anticholinergics 18.5 79
Antibiotics 30.5 83
Inhaled steroids 10.7 71
LABA 547.2 13
Oral steroids 10.5 94
SABA 14.7 93
Theophyllines 7.9 29
Hospital time Per day (Mean length of stay)
Emergency room 526 90 (9.9 h)
Respiratory ward 348.5 38 (7.6 h)
Intensive care unit 1003 3 (47.5 h)
Other direct costs Per test
PEF 19.7 99
Spirometry 13.3 40
Outpatient visit 215 92
Mean cost of medications and devices, h 866.9
95% CI, h 714.4, 1057.4
Mean cost hospital time, h 2741.3
95% CI, h 2399.6, 3077.0
Other direct costs, h 200.7
95% CI, h 166.1, 239.5
Mean total direct cost, h 3809.0
95% CI, h 3379.0, 4301.1
Seventy-two people included in economic analysis, mean duration of exacerbation 13.2 days (SD 9.1).
For exacerbation, most commonly hydrocortisone (used by 81% of patients, mean use 2774 units), Ventolin (used by 78% of
patients, mean use 139 units), Atrovent (used by 75% of patients, mean use 19,315 units) and Augmentin (used by 60% of
patients, mean use 7520 units).
Table 19 Cost of an exacerbation managed in secondary care in Latvia.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics — —
Antibiotics 19.8 (38.0) 37
Inhaled steroids 7.0 (13.5) 71
LABA 20.1 (38.6) 17
Oral steroids 9.3 (17.8) 84
SABA 3.3 (6.4) 66
Theophyllines 0.8 (1.6) 98
Hospital time Per day (Mean length of stay)
Emergency room 200.00 (383.53) 1 (24 h)
Respiratory ward 15.00 (28.76) 53 (9.2 days)
Intensive care unit 200.00 (383.53) 2 (36.5 h)
Other direct costs Per test
PEF 0.31 (0.59) 35
Spirometry 1.20 (2.30) 60
Outpatient visit 2.00 (3.84) 33
Mean cost of medications and devices 153.5 (294.4)
95% CI, national currency (h) 118.2, 197.4 (226.6, 378.5)
Mean cost hospital time 158.4 (303.8)
95% CI, national currency (h) 143.8, 176.3 (275.8, 338.0)
Other direct costs 10.0 (19.3)
95% CI, national currency (h) 7.8, 12.4 (15.0, 23.7)
Mean total direct cost 322.0 (617.6)
95% CI, national currency (h) 282.7, 367.9 (542.1, 705.5)
Ninety-nine people included in economic analysis, mean duration of exacerbation 18.3 days (SD 8.8).
For exacerbation, most commonly Euphyllin (used by 85% of Patients, mean use 2950 units) and Prednisolone (used by 44% of
patients, mean use 1157 units).
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Table 20 Cost of an exacerbation managed in secondary care in Norway.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics 79.1 (9.9) 57
Antibiotics 574.7 (72.1) 21
Inhaled steroids 209.8 (26.3) 34
LABA 198.5 (24.9) 12
Oral steroids 282.9 (35.5) 74
SABA 70.1 (8.8) 68
Theophyllines 558.8 (70.1) 41
Hospital time Per day (Mean length of stay)
Emergency room 11900 (1492.19) 84 (2.5 h)
Respiratory ward 2590 (324.77) 63 (6.5 days)
Intensive care unit 11900 (1492.19) 10 (71.8 h)
Other direct costs Per test
PEF 135 (16.93) 63
Spirometry 85 (10.66) 73
Outpatient visit 139 (17.40) 65
Mean cost of medications and devices 5780.5 (724.8)
95% CI, national currency (h) 4675.1, 7192.3 (586.2, 901.9)
Mean cost hospital time 21540.3 (2701.0)
95% CI, national currency (h) 16309.9, 27777.4 (2045.2, 3483.1)
Other direct costs 937.5 (117.6)
95% CI, national currency (h) 740.0, 1172.1 (92.8, 147.0)
Mean total direct cost 28258.3 (3543.4)
95% CI, national currency (h) 22510.9, 34890.7 (2822.7, 4375.1)
Eighty-two people included in economic analysis, mean duration of exacerbation 11.9 days (SD 15.3).
For exacerbation, most commonly Prednisolone (used by 63% of patients, mean use 339 units), Atrovent (57% of patients,
mean use 843 units) and Ventolin (used by 40% of patients, mean use 36 units).
Table 21 Cost of an exacerbation managed in secondary care in Russia.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics — —
Antibiotics 636.3 (27.1) 8
Inhaled steroids 179.3 (7.6) 54
LABA 48.4 (2.1) o1
Oral steroids 406.7 (17.3) 77
SABA 190.4 (8.1) 74
Theophyllines 158.6 (6.8) 83
Hospital time Per day (Mean length of stay)
Emergency room 500 (21.29) —
Respiratory ward 250 (10.65) 33 (16.4 days)
Intensive care unit 500 (21.29) 11 (41.1 h)
Other direct costs Per test
PEF 12.00 (0.51) 36
Spirometry 32.10 (1.37) 68
Outpatient visit 20.00 (0.85) 60
Mean cost of medications and devices 11820.3 (503.4)
95% CI, national currency (h) 5615.1, 19552.2 (239.1, 832.7)
Mean cost hospital time 4150.6 (176.8)
95% CI, national currency (h) 3876.7, 4445.2 (165.1, 189.3)
Other direct costs 302.5 (12.9)
95% CI, national currency (h) 268.2, 341.8 (11.4,14.6)
Mean total direct cost 16273.3 (693.1)
95% CI, national currency (h) 9937.0, 24102.8 (423.2, 1026.5)
One hundred and forty-nine people included in economic analysis, mean duration of exacerbation 18.1 days (SD 9.1.).
For exacerbation, most commonly Euphyllin (used by 66% of patients, mean use 2395 units) and Prednisolone (used by 50% of
patients, mean use 1140 units).
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Table 22 Cost of an exacerbation managed in secondary care in Slovakia.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics 453.0 (10.4) 11
Antibiotics 1365.8 (31.4) 45
Inhaled steroids 493.1 (11.3) 64
LABA 317.8 (7.3) 26
Oral steroids 853.4 (19.6) 66
SABA 12921.1 (296.7) 59
Theophyllines 78.8 (1.8) 63
Hospital time Per day (Mean length of stay)
Emergency room 7810 (179.33) 4 (2.3 h)
Respiratory ward 1058 (24.29) 100 (18.7 days)
Intensive care unit 7810 (179.33) 4 (168 h)
Other direct costs Per test
PEF 118 (2.71) 50
Spirometry 505 (11.60) 90
Outpatient visit 26 (0.59) 17
Mean cost of medications and devices 13804.1 (317.0)
95% CI, national currency (h) 4734.7, 28454.5 (108.7, 653.3)
Mean cost hospital time 22216.9 (510.1)
95% CI, national currency (h) 18823.0, 26425.4 (432.2, 606.8)
Other direct costs 4538.5 (104.2)
95% CI, national currency (h) 3601.0, 5391.4 (82.7, 123.8)
Mean total direct cost 40559.5 (931.3)
95% CI, national currency (h) 30019.2, 55749.4 (689.3, 1280.1)
One hundred and one people included in economic analysis, mean duration of exacerbation 14.9 days (SD 7.7).
For exacerbation, most commonly Syntophyllin (used by 42% of patients, mean use 4160 units) and Hydrocortisone (used by
41% of patients, mean use 1734 units).
Table 23 Cost of an exacerbation managed in secondary care in Slovenia.
Unit cost, national currency (h) % patients using resource
Main medications Mean per person
Anticholinergics — —
Antibiotics 5861.0 (28.5) 32
Inhaled steroids 2849.0 (13.9) 75
LABA 1529.5 (7.4) 37
Oral steroids 3921.1 (19.1) 73
SABA 631.5 (3.1) 81
Theophyllines 630.7 (3.1) 28
Hospital time Per day (Mean length of stay)
Emergency room 35494 (172.81) 5 (20.2 h)
Respiratory ward 35494 (172.81) 50 (10.8 days)
Intensive care unit 35494 (172.81) 5 (32.4 h)
Other direct costs Per test
PEF 2550 (12.42) 76
Spirometry 2550 (12.42) 94
Outpatient visit 7000 (34.08) 72
Mean cost of medications and devices 19455 (94.7)
95% CI, national currency (h) 15802, 23216 (76.9, 113.0)
Mean cost hospital time 208874 (1016.9)
95% CI, national currency (h) 163357, 260721 (795.3, 1269.4)
Other direct costs 64626 (314.6)
95% CI, national currency (h) 52842, 76244 (257.3, 371.2)
Mean total direct cost 292956 (1426.3)
95% CI, national currency (h) 235185, 355705 (1145.0, 1731.8)
One hundred and nine people included in economic analysis, mean duration of exacerbation 19.3 days (SD 10.3).
For exacerbation, most commonly Medrol (used by 65% of patients, mean use 68 units), Flixotide (used by 50% of patients,
mean use 19,309 units) and Berodual (used by 40% of patients, mean use 6320 units).
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with a healthcare professional in primary or
secondary care, thus suggesting that their asthma
was not under control. Whilst this study gives no
indication of the incidence of exacerbations or how
often control of asthma is sub-optimal, numerous
studies have shown that many patients continue to
suffer significant levels of symptoms with an
adverse impact on quality of life.5,6 However,
recent studies with combination therapies have
shown that it is possible for guideline-defined
control to be achieved.25,26 If such a management
approach is used systematically, few patients
should suffer exacerbations.
In conclusion, this study provided country-
specific information on local practice and costs
of managing exacerbations of asthma. The results
showed that asthma exacerbations are costly to
manage, particularly in secondary care, suggesting
that therapies able to reduce the frequency or
severity of exacerbations may bring economic
benefits, as well as improved quality of life.
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